<DOC>
	<DOC>NCT02006667</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of a chemotherapy regimen of intravenous Herceptin, cisplatin and gemcitabine in patients with metastatic urothelial cancer. The anticipated time on study treatment is until disease progression.</brief_summary>
	<brief_title>A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adult patients with &gt;=18 years of age; metastatic urothelial carcinoma; measurable metastases or local recurrent disease; no prior chemotherapy for metastatic disease; HER2 overexpression (IHC [2+] or [3+]). concomitant chemotherapy or immunotherapy; active or uncontrolled infection; solely CNS metastases; clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea; coexisting malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>